Germanium Organic/Ge-132 / propagermanium (organogermanium) Cancer Research Results

Ge-132, Germanium Organic/Ge-132 / propagermanium (organogermanium): Click to Expand ⟱
Features: organic

Organic Germanium

Common names include germanium-132 (Ge-132) and germanium sesquioxide(listed seperately).
Small amounts of germanium are found in certain minerals and plant products, including:
argyrodite
germanite
garlic
ginseng
aloe
comfrey

"At present, germanium is widely recognized as a vital trace element, which is particularly essential for the normal functioning of the immune system and plays a significant role in cancer prevention"(note this statement is not universally accepted)

Organogermanium / Ge-132 / propagermanium — comprises synthetic carbon-containing germanium compounds based on carboxyethylgermanium or oxygermylpropionic-acid structures. Ge-132, formally poly-trans-[(2-carboxyethyl)germasesquioxane] and commonly called carboxyethylgermanium sesquioxide or bis(2-carboxyethylgermanium) sesquioxide, hydrolyzes in aqueous environments to 3-(trihydroxygermyl)propanoic acid. Propagermanium is the pharmaceutical 3-oxygermylpropionic acid polymer and is marketed in Japan as Serocion for selected HBe-antigen-positive chronic hepatitis B patients. Ge-132 and propagermanium are closely related organogermanium preparations but should not be assumed to be chemically, pharmaceutically or clinically interchangeable with every product marketed as “organic germanium.” Purified organogermanium has substantially lower experimental renal toxicity than germanium dioxide, but germanium is not an essential nutrient and product contamination with inorganic germanium remains an important safety concern.

Primary mechanisms (ranked):

  1. Inhibition of CCL2-mediated CCR2 signaling by propagermanium, reducing monocyte chemotaxis, tumor-associated myeloid-cell recruitment and formation of prometastatic niches.
  2. Immune activation through increased IL-1, IL-2 and interferon production, with stimulation of cytotoxic T lymphocytes, natural killer cells, macrophages and antibody-mediated antigen clearance.
  3. Macrophage- and T-lymphocyte-dependent antitumor activity in murine Ge-132 models, occurring predominantly through host immune modulation rather than direct tumor-cell cytotoxicity.
  4. Antioxidant and cytoprotective modulation in normal cells, including reduced ROS, inflammatory signaling and oxidative-stress-induced apoptosis.
  5. Reversible binding of the Ge-132 hydrolysate to physiological cis-diol compounds and sequestration of sulfide species, potentially contributing to metabolic, inflammatory and analgesic effects.

Bioavailability / PK relevance: Ge-132 and propagermanium produce measurable systemic germanium exposure after oral administration but have preparation-specific pharmacokinetics. After very large single Ge-132 doses in healthy volunteers, peak plasma germanium occurred within approximately 0.75–2 hours and the terminal half-life was approximately 5–6 hours, while less than 11% of the administered germanium was recovered in urine within 24 hours. Pharmaceutical propagermanium at a 15 mg single dose reached peak plasma concentration near 3 hours with a half-life near 2.4 hours; its structural unit was reportedly not metabolized, and urinary and fecal elimination were substantial. Because renal clearance contributes materially, exposure may increase with severe renal impairment.

In-vitro vs systemic exposure relevance: Ge-132 is hydrolyzed in water and biological fluids, so experiments using Ge-132 or its hydrolysate must be interpreted according to the actual chemical species and concentration present. Antioxidant, sulfide-binding and cis-diol-complex experiments commonly use micromolar-to-millimolar concentrations that may exceed exposure from ordinary supplement use. The CCL2-related oncology rationale is not primarily based on direct tumor-cell cytotoxicity; it depends on modulation of monocytes, macrophages, myeloid-derived suppressor cells and the tumor microenvironment.

Clinical evidence status: Preclinical for anticancer efficacy, with limited Phase I human oncology evidence. A perioperative dose-escalation study in 12 patients with primary breast cancer found propagermanium doses of 30–90 mg/day feasible without dose-limiting toxicity, but it was not designed to demonstrate reduced recurrence, metastasis or survival benefit. A single historical remission report involving oral germanium sesquioxide cannot establish causality. Propagermanium has prescription-drug status in Japan for improvement of viral markers in selected HBe-antigen-positive chronic hepatitis B, not for cancer. No validated randomized cancer trial supports Ge-132 or propagermanium as an anticancer treatment or adjunct.

Organogermanium Mechanistic Profile

Rank Pathway / Axis Cancer Cells Normal Cells TSF Primary Effect Notes / Interpretation
1 CCL2 and CCR2 signaling ↓ prometastatic signaling indirectly
↓ myeloid-supported progression		 ↓ CCL2-induced monocyte chemotaxis R Suppression of inflammatory cell recruitment Propagermanium appears to act through CCR2-associated glycosylphosphatidylinositol-anchored proteins rather than conventional competitive occupancy of the CCL2-binding site.
2 Tumor-associated macrophages and myeloid suppressor cells ↓ premetastatic niche formation
↓ metastasis (model-dependent)		 ↓ monocyte and macrophage tissue recruitment G Tumor-microenvironment modulation The antimetastatic rationale is supported mainly by animal models. The small breast-cancer Phase I trial demonstrated feasibility and biomarker effects, not clinical anticancer efficacy.
3 Interferon and cytokine induction ↓ tumor survival indirectly (model-dependent) ↑ IFN-α
↑ IFN-β
↑ IFN-γ
↑ IL-1
↑ IL-2		 G Innate and adaptive immune activation Most mechanistic evidence derives from murine Ge-132 or propagermanium studies and the Japanese propagermanium pharmacology dossier.
4 Cytotoxic T cells and NK cells ↓ tumor or infected-cell survival indirectly ↑ cytotoxic T-cell induction
↑ NK-cell activity		 G Cell-mediated cytotoxicity Propagermanium is clinically classified as an immune modulator rather than a directly acting antiviral or cytotoxic cancer drug.
5 Macrophage antitumor function ↓ tumor growth (model-dependent) ↑ macrophage activation
↑ phagocytic activity		 G Host-mediated tumor suppression Murine Ge-132 antitumor effects were substantially dependent on macrophages and T lymphocytes. Direct activity against human cancer cells is not established.
6 Oxidative stress and apoptosis ↔ mixed or insufficient evidence ↓ ROS
↓ oxidative apoptosis
↓ cellular injury		 R Antioxidant cytoprotection Purified Ge-132 or repagermanium protected normal cultured cells against oxidative injury. This should not be interpreted as tumor-selective ROS elevation or cancer-cell killing.
7 Inflammatory cytokines ↓ tumor-promoting inflammation (context-dependent) ↓ IL-6
↓ inflammatory injury		 G Anti-inflammatory modulation Anti-inflammatory effects may coexist with increased immune-stimulatory cytokines because the direction depends on cell type, stimulus, disease state and organogermanium preparation.
8 Physiological cis-diol complex formation ↔ uncertain ↔ adrenaline
↔ ATP
↔ nucleoside interactions		 R Reversible molecular complex formation The Ge-132 hydrolysate forms complexes with selected cis-diol-containing molecules. The clinical significance and relevance to cancer remain uncertain.
9 Sulfide and Cav3.2 signaling ↔ uncertain ↓ sulfide-dependent Cav3.2 activation
↓ pain signaling		 R Experimental analgesic activity THGP can sequester sulfide species and suppress Cav3.2-dependent pain in experimental systems. This is a secondary non-cancer mechanism.
10 Clinical Translation Constraint ↔ efficacy unproven ↑ exposure with renal impairment
↑ hepatic risk in susceptible patients		 G Restricted therapeutic applicability Cancer data are predominantly preclinical. Commercial product purity is variable, inorganic germanium contamination can negate the apparent safety advantage, and pharmaceutical propagermanium carries disease-specific hepatic warnings.

P: 0–30 min    R: 30 min–3 hr    G: >3 hr
Scientific Papers found: Click to Expand⟱
789- Ge-132,    Complete remission of pulmonary spindle cell carcinoma after treatment with oral germanium sesquioxide
- Case Report, SCC, NA
Remission↑,
790- Ge-132,    A Toxicological Evaluation of Germanium Sesquioxide (Organic Germanium)
- vitro+vivo, NA, NA
other↓, *toxicity↓,
791- Ge-132,    Germanium Sesquioxide Organic Germanium
other↝,
792- Ge-132,    The role of germanium in diseases: exploring its important biological effects
other↓,
7117- Ge-132,    Organogermanium suppresses cell death due to oxidative stress in normal human dermal fibroblasts
- in-vitro, Nor, NA
*IL6↓, *Apoptosis↓, *toxicity↓, Imm↑, IFN-γ↑, NK cell↑, AntiTum↑, Pain↓, *Wound Healing↑,
7124- Ge-132,    Physiological Activity of Trace Element Germanium including Anticancer Properties
- Review, Var, NA
*toxicity↓, Risk↓, Dose↝, AntiCan↑, AntiTum↑, Inflam↓, OXPHOS↝, *toxicity↓, *toxicity↓, other↑, eff↑, *Bacteria↓, *AntiFungal↑, eff↑, eff↑, ROS↑, eff↑, toxicity↝, *H2O2↓, *ROS↓, Warburg↓,
7125- Ge-132,    A review of public and environmental consequences of organic germanium
- Review, Nor, NA
*toxicity↓, other↝, Imm↑, anemia↓,
7126- Ge-132,    Immune activation of Bio-Germanium in a randomized, double-blind, placebo-controlled clinical trial with 130 human subjects: Therapeutic opportunities from new insights
- Trial, Nor, NA
AntiTum↑, AntiCan↑, *AntiAge↑, *AntiViral↑, *Inflam↓, *NK cell↑, *Imm↑, *TNF-α↑,
7127- Ge-132,    Synthesis and Evaluation of Novel Organogermanium Sesquioxides As Antitumor Agents
- vitro+vivo, Var, NA
eff↑, BioAv↑, RadioS↑,
7128- Ge-132,    Pharmacokinetics of germanium after po beta-carboxyethylgermanium sesquioxide in 24 Chinese volunteers
- Trial, Nor, NA
*Half-Life↝,
7129- Ge-132,    Antitumor activity of Ge-132, a new organogermanium compound, in mice is expressed through the functions of macrophages and T lymphocytes
- in-vivo, lymphoma, NA
eff↑,
7130- Ge-132,    Phase I dose-escalation trial to repurpose propagermanium, an oral CCL2 inhibitor, in patients with breast cancer
- Trial, BC, NA
IL6↓, TumMeta↓, Dose↝, MCP1/CCL2↓,
7131- Ge-132,    Antioxidant Activity of Ge-132, a Synthetic Organic Germanium, on Cultured Mammalian Cells
- in-vitro, Nor, CHO K1
*ROS↓,
7132- Ge-132,    Organogermanium compound, Ge-132, forms complexes with adrenaline, ATP and other physiological cis-diol compounds
- in-vitro, Nor, NA
*other?,
7133- Ge-132,    Organogermanium, Ge-132, promotes the clearance of senescent red blood cells via macrophage-mediated phagocyte activation
- in-vitro, Nor, RAW264.7
*RBC↑, *antiOx↑,

Showing Research Papers: 1 to 15 of 15

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 15

Pathway results for Effect on Cancer / Diseased Cells:


NA, unassigned(tgid=0) ⓘ

anemia↓, 1,  

Redox & Oxidative Stress(tgid=1) ⓘ

OXPHOS↝, 1,   ROS↑, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

Warburg↓, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

other↓, 2,   other↑, 1,   other↝, 2,  

Migration(tgid=13) ⓘ

TumMeta↓, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

IFN-γ↑, 1,   IL6↓, 1,   Imm↑, 2,   Inflam↓, 1,   MCP1/CCL2↓, 1,   NK cell↑, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↑, 1,   Dose↝, 2,   eff↑, 6,   RadioS↑, 1,  

Clinical Biomarkers(tgid=22) ⓘ

IL6↓, 1,  

Functional Outcomes(tgid=23) ⓘ

AntiCan↑, 2,   AntiTum↑, 3,   Pain↓, 1,   Remission↑, 1,   Risk↓, 1,   toxicity↝, 1,  
Total Targets: 25

Pathway results for Effect on Normal Cells:


NA, unassigned(tgid=0) ⓘ

RBC↑, 1,  

Redox & Oxidative Stress(tgid=1) ⓘ

antiOx↑, 1,   H2O2↓, 1,   ROS↓, 2,  

Cell Death(tgid=5) ⓘ

Apoptosis↓, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

other?, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

IL6↓, 1,   Imm↑, 1,   Inflam↓, 1,   NK cell↑, 1,   TNF-α↑, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

Half-Life↝, 1,  

Clinical Biomarkers(tgid=22) ⓘ

IL6↓, 1,  

Functional Outcomes(tgid=23) ⓘ

AntiAge↑, 1,   toxicity↓, 6,   Wound Healing↑, 1,  

Infection & Microbiome(tgid=24) ⓘ

AntiFungal↑, 1,   AntiViral↑, 1,   Bacteria↓, 1,  
Total Targets: 19

Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:429  Target#:%  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page